News | November 19, 2009

Updated Guidelines Include Latest Findings on Treating Heart Attacks

November 18, 2009 – New, joint guidelines from the American College of Cardiology (ACC), the American Heart Association (AHA) and the Society for Cardiovascular Angiography and Interventions (SCAI), focus updates on the management of patients with ST-elevation myocardial infarction (STEMI) and percutaneous coronary intervention (PCI).

The guideline update incorporates several changes, including:

• Use of a fractional flow reserve (FFR) pressure wires to gauge whether plaque build-up in a particular area is actually interfering with blood flow and if a stent is needed.

• Use of aspiration thrombectomy to remove clots causing a heart attack before a stent is placed.

• Use of the new anti-clotting medication prasugrel (Effient), an alternative to clopidogrel (Plavix) for patients treated with PCI.

• Recommendations for use of a variety of blood thinners and anti-clotting medications before, during or after PCI.

• There are broader recommendations on the types of X-ray dye that may be safely used to view the coronary arteries during PCI in patients with chronic kidney disease.

The fast-track document, released at AHA 2009, will help healthcare providers interpret the latest clinical research on two important and inter-related areas of cardiology, and quickly put this new knowledge into clinical practice.

“The focused update is a way of responding quickly to new information that will benefit patients,” said Sidney C. Smith, Jr., M.D., a professor of medicine and director of the Center for Cardiovascular Science and Medicine at the University of North Carolina at Chapel Hill and chair of the writing group. “We were able to look over a year of major studies and incorporate the most valuable findings into the existing guidelines.”

One of the most important new recommendations is for each community to develop an organized system of emergency care for patients who are having a heart attack, modeled after the AHA’s Mission: Lifeline initiative and the ACC’s Door-to-Balloon (D2B) campaign. This plan would include protocols for identifying heart attack patients even before they reach the hospital and directing ambulances to medical centers capable of rapidly performing PCI to open the blocked coronary artery. The plan would also include protocols for managing heart attack patients who initially arrive at hospitals not equipped to perform PCI, including arrangements for rapid transfer to a PCI center, whenever possible.

In addition, the guidelines address the management of patients who initially go to a non-PCI hospital and cannot be transferred quickly. These patients should be treated with clot-busting drugs, according to the guidelines. Afterward, if patients are judged to be high-risk, it is reasonable to transfer them to a PCI center without delay, rather than waiting to observe whether the clot-busters are successful, as is common practice today.

Over the last few years, communities around the country have begun to put in place organized systems of heart attack care, but they are not yet widespread. Community members can play an important part in getting the ball rolling, said Frederick G. Kushner, M.D., medical director of The Heart Clinic of Louisiana and a clinical professor of medicine at Tulane School of Medicine in New Orleans and co-chair of the writing group.

“Patients should become advocates and urge their local hospital to become part of a community network that follows the recommendations of the Mission: Lifeline program,” he said. “It’s the best way to quickly activate the chain of events that are critical to opening a blocked artery causing a heart attack.”

Another major change in the guidelines is greater acceptance of stenting for the treatment of the left main coronary artery. The left main is one of the two coronary arteries that come directly off of the aorta, before it splits into smaller branches. Because a complete blockage of the left main coronary artery would cut off the blood supply to the majority of the heart, bypass surgery has long been the recommended treatment for patients with a narrowing in this artery. Recent studies, however, have shown that in certain patients, stenting of the left main is safe and effective. As a result, the new guidelines now allow for left main stenting as an option when procedural complications are likely to be low and the patient faces an increased risk if treated surgically.

“There is mounting evidence that stenting of the left main coronary artery, under certain circumstances, does carry a reasonably good outcome,” said Spencer B. King, III, M.D., president of the Saint Joseph’s Heart and Vascular Institute and a professor of medicine emeritus at Emory University School of Medicine in Atlanta and co-chair of the writing group. “Now stenting might be considered, based on the specific anatomy of the coronary arteries and the risk profile of the patient.”

“People have heard a lot about evidence-based medicine,” said Dr. King. “These guidelines are a distillation of all the relevant evidence. They will help physicians to make the best choices for their patients.”

“The new process of rapidly updating guidelines will allow practioners the opportunity to utilize contemporary evidence-based medicine to make critical decisions. Our patients will have more treatment options because the new guidelines include provisions for stenting left main and complex three-vessel coronary artery disease and stress the use of physiologic lesion assessment to optimize clinical outcomes,” said Steven R. Bailey, M.D., FACC, FSCAI, chief of the Dolph and Janey Briscoe Division of Cardiology at University of Texas Health Sciences Center at San Antonio, SCAI president, and a representative of SCAI on the writing committee.

Dr. Smith was chair of both the PCI Writing Group and the ACC/AHA Task Force on Practice Guidelines. Dr. Kushner was co-chair of the STEMI Writing Group and Dr. King was co-chair of the PCI Writing Group.

The new focused guidelines update will be published in the Dec. 1 issue of Journal of the American College of Cardiology, the Dec. 1 issue of Circulation: Journal of the American Heart Association, and online Nov. 18 in Catheterization and Cardiovascular Interventions. It is also available on the Web sites of the American College of Cardiology (www.acc.org), the American Heart Association (my.americanheart.org), and the Society for Cardiovascular Angiography and Interventions (www.scai.org).

Related Content

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
Overlay Init